🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

STERIS plc STE SPX

Healthcare · Medical Devices · United States
https://www.steris.com

STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.

READ MORE ›
$212.73
-12.59% 1Y

Market & Price

Market Cap
$20.88B
Current Price
$212.73
High / Low (52W)
$267.97 / $201.85
Beta
0.95

Valuation

Stock P/E
26.83
Industry PE
23.65
Forward P/E
17.58
PEG Ratio
1.46
Book Value
$72.93
Price to Book
2.92
P/S
3.52
EV/EBITDA
16.27
Dividend Yield
1.18%

Profitability & Returns

ROCE
9.67%
ROE
11.37%
ROA
6.63%
Profit Margin
13.18%
Op Margin
20.00%
EPS (Latest Qtr)
$2.24
EPS (TTM)
$7.93

Balance Sheet & Liquidity

Debt/Equity
0.27
Quick Ratio
1.34
Current Ratio
2.09
Debt
$1.93B
Total Assets
$10.15B
Current Assets
$2.00B
Working Capital
$978.59M

Ownership

Promoter Holding
0.30%
Chg in Prom Hold
-
FII / Inst Holding
100.29%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$22.34B
Total Revenue (TTM)
$5.94B
EBITDA
$1.37B
Free Cash Flow
$587.57M
Operating Cash Flow
$1.34B
Shares Outstanding
98.08M
Gross Margin
44.28%
Payout Ratio
31.02%

Growth (CAGR)

Revenue 5Y
8.93%
Profit 5Y
36.09%
Revenue (YoY)
7.30%
Earnings (YoY)
52.20%

PROS

  • Profit CAGR of 36.1% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 STE STERIS plc SPX 212.73 26.83 $20.88B 1.18% 9.67% 11.37% 8.93% 36.09%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 607.96M661.90M715.97M638.76M678.96M696.24M768.21M696.80M736.84M774.26M822.99M668.93M756.13M808.92M873.53M968.42M1.20B1.21B1.21B1.05B1.09B1.11B1.28B1.18B1.24B1.30B1.42B1.28B-1.37B1.48B1.39B1.46B1.50B-
Cost of Revenue -----------------------------760.20M839.32M763.10M814.40M840.70M-
Gross Profit 255.77M278.22M292.37M269.05M284.66M287.00M334.72M306.89M318.67M331.35M363.09M287.38M330.04M345.86M379.82M426.28M480.34M538.11M571.62M473.82M482.31M478.19M546.40M529.00M546.23M560.03M582.90M572.40M-610.30M641.21M628.00M645.90M655.50M-
Operating Expenses -----------------------------362.90M361.59M380.20M377.90M381.80M-
Operating Income ---94.42M106.58M69.58M-110.09M126.73M142.39M-115.82M141.26M147.03M-14.32M116.50M202.93M-158.40M-306.42M190.80M-197.76M191.55M226.47M-185.50M-247.40M279.62M247.80M268.00M273.70M-
EBITDA -----------------------------373.70M336.77M367.20M389.70M394.70M-
Interest Expense -----------------------------19.10M17.11M15.90M14.90M14.90M-
Pretax Income -----------------------------228.70M197.31M231.90M253.10M257.80M-
Tax Provision -----------------------------55.40M50.45M53.90M60.60M63.50M-
Net Income 58.08M94.78M73.60M69.99M77.46M47.86M108.75M85.37M94.77M104.93M122.59M89.60M105.86M114.50M87.44M-21.81M69.81M143.62M52.26M111.26M-315.29M123.83M187.22M123.55M115.32M140.74M-1.38M145.40M-173.50M145.67M177.40M191.90M192.80M-
Diluted EPS 0.681.110.860.820.910.561.271.001.111.231.431.051.231.331.02-0.240.691.420.521.10-3.151.241.881.251.161.42-0.011.46--1.481.791.941.962.24
R&D Expense ---16.22M15.77M15.17M-15.59M16.25M16.49M-16.23M16.14M16.44M-18.19M18.83M24.82M-24.75M24.93M25.51M-24.69M26.27M25.25M-25.60M27.00M27.40M-26.40M28.20M29.50M-

Profit & Loss (Annual)

Figures in USD.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 2.61B2.62B2.78B3.03B3.11B4.22B4.54B5.14B5.46B-
Cost of Revenue -----2.34B2.56B2.92B3.06B-
Gross Profit 1.03B1.09B1.17B1.32B1.34B1.88B1.98B2.22B2.40B-
Operating Expenses -----1.41B1.19B1.36B1.44B-
Operating Income 226.21M399.88M411.02M537.05M548.37M477.86M791.59M862.16M960.84M-
EBITDA -----1.01B1.34B1.41B1.36B-
Interest Expense -----89.49M110.83M144.35M86.26M-
Pretax Income -----366.80M680.27M702.81M796.21M-
Tax Provision -----82.34M124.07M149.53M184.65M-
Net Income 109.97M290.92M303.72M407.66M397.40M243.89M107.03M378.24M614.64M-
Diluted EPS 1.283.393.554.764.63-1.073.816.207.93
R&D Expense 59.40M60.78M63.04M65.55M66.33M86.66M98.48M103.68M107.65M-

Compounded Sales Growth

5 Years:8.93%
1 Year:7.30%

Compounded Profit Growth

5 Years:36.09%
1 Year:52.20%

Stock Price Performance

1 Year:-12.59%
6 Months:-20.36%
3 Months:-15.70%
1 Month:+0.04%

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets --5.20B5.07B5.44B6.57B11.42B10.82B11.06B10.15B
Current Assets ------1.88B2.01B2.87B2.00B
Cash & Equivalents 248.84M282.92M201.53M220.63M319.58M220.53M348.32M208.36M207.02M171.70M
Inventory ------575.00M604.41M674.53M581.33M
Receivables ------799.04M864.99M1.01B1.04B
Total Liabilities --1.98B1.89B2.02B2.68B4.88B4.73B4.75B3.53B
Current Liabilities --398.46M465.20M503.61M577.92M922.22M861.84M931.13M1.02B
Long Term Debt --1.32B1.18B1.15B1.65B2.95B3.02B3.12B1.92B
Total Debt ------3.28B3.25B3.38B2.20B
Total Equity --3.21B3.18B3.41B3.88B6.53B6.08B6.30B6.60B
Shares Outstanding ------100.07M98.63M98.88M98.30M

Cash Flows (Annual)

Figures in USD.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow 424.09M457.63M539.50M590.56M689.64M684.81M756.95M973.27M1.15B
Investing Cash Flow -104.25M-203.83M-213.22M-319.74M-1.15B-666.56M-383.33M-887.36M388.77M
Financing Cash Flow -267.10M-356.18M-294.79M-163.15M345.62M115.83M-498.72M-85.19M-1.57B
Capital Expenditure -172.90M-165.46M-189.72M-214.52M-239.26M-287.56M-361.97M-360.33M-370.09M
Free Cash Flow 251.19M292.18M349.79M376.04M450.38M397.25M394.98M612.95M778.00M
Net Change in Cash -----134.08M-125.10M727.00K-35.50M
Share Buybacks 97.51M65.48M81.49M51.24M14.65M55.78M308.56M11.77M211.32M

Ratios (Annual)

Figures in %.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % 39.3%41.7%42.2%43.6%43.2%44.6%43.7%43.2%44.0%-
Operating Margin % 8.7%15.3%14.8%17.7%17.6%11.3%17.5%16.8%17.6%-
Net Margin % 4.2%11.1%10.9%13.5%12.8%5.8%2.4%7.4%11.3%-
ROE % -9.1%9.6%12.0%10.2%3.7%1.8%6.0%9.3%-
ROCE % -8.3%8.9%10.9%9.1%4.6%7.9%8.5%10.5%-

Shareholding Pattern

Insiders
0.30%
Institutions
100.29%
Public Float
100.59%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.20% 9.03M $1.92B
2 Vanguard Capital Management LLC 6.49% 6.37M $1.35B
3 State Street Corporation 5.09% 4.99M $1.06B
4 Vanguard Portfolio Management LLC 5.05% 4.95M $1.05B
5 Morgan Stanley 4.48% 4.39M $934.79M
6 Massachusetts Financial Services Co. 4.09% 4.01M $853.12M
7 Wellington Management Group, LLP 2.93% 2.87M $611.25M
8 Orbis Allan Gray Ltd 2.64% 2.59M $551.59M
9 Geode Capital Management, LLC 2.63% 2.58M $549.21M
10 Generation Investment Management LLP 2.35% 2.31M $491.08M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for STE

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks